摘要
目的探究对比国产和进口氢氯吡格雷片治疗冠心病的临床疗效和经济性。方法519例冠心病患者,根据治疗药物不同分为A组(266例)和B组(253例)。两组患者均给予规范的冠心病二级预防药物治疗,其中,抗血小板聚集用药,A组采用进口氢氯吡格雷,B组采用国产氢氯吡格雷。比较两组入院时和治疗1个月后血液流变学指标(血小板聚集率、全血粘度、血浆粘度)及不良反应发生情况,分析两组治疗12个月后成本-效果比。结果入院时,两组血小板聚集率、全血粘度、血浆粘度比较差异均无统计学意义(P>0.05);治疗1个月后,两组血小板聚集率、全血粘度、血浆粘度均显著低于入院时,差异具有统计学意义(P<0.05),但两组血小板聚集率、全血粘度、血浆粘度比较差异均无统计学意义(P>0.05)。治疗12个月后,A组成本-效果比为5984.05,B组成本-效果比为3905.06,两组患者临床疗效相当,但B组成本-效果比低于A组,说明使用国产氢氯吡格雷是成本效果最优方案。现假设药品价格下调10%,B组成本-效果比为3514.56,低于A组的5385.65,说明使用国产氢氯吡格雷仍是成本效果最优方案。两组的不良反应发生率比较,差异无统计学意义(P>0.05)。结论在冠心病的治疗中,采用进口或国产氢氯吡格雷片具有相当的临床治疗效果,但使用国产氢氯吡格雷具有更低治疗成本,且更适宜推广。
Objective To investigate the clinical efficacy and economics of domestic and imported clopidogrel tablets in the treatment of coronary heart disease.Methods A total of 519 patients with coronary heart disease were divided into group A(266 cases)and group B(253 cases)according to different treatment drugs.Patients in both groups were treated with standardized secondary prevention drugs for coronary heart disease,of which,group A was treated with imported clopidogrel,group B was treated with domestic clopidogrel.Hemorheology indexes(platelet aggregation rate,whole blood viscosity,plasma viscosity)on admission and 1 month after treatment,and occurrence of adverse reactions were compared between the two groups.The costeffectiveness ratio 12 months after treatment of the two groups were analyzed.Results On admission,there was no statistically significant difference in platelet aggregation rate,whole blood viscosity and plasma viscosity between the two groups(P>0.05).1 month after treatment,the platelet aggregation rate,whole blood viscosity and plasma viscosity of the two groups were significantly lower than those on admission,and the difference was statistically significant(P<0.05).But there was no statistically significant difference in platelet aggregation rate,whole blood viscosity and plasma viscosity between the two groups(P>0.05).12 months after treatment,the cost-effectiveness ratio of group A was 5984.05,which was 3905.06 of group B.The clinical efficacy of the two groups was similar,but the cost-effectiveness ratio of group B was lower than that of group A,indicating that domestic clopidogrel was the best cost-effectiveness scheme.There was no statistically significant difference in incidence of adverse reactions between the two groups(P>0.05).Conclusion Imported and domestic clopidogrel tablets shows equal clinical effect in the treatment of coronary heart disease,but domestic hydroclopidogrel has lower treatment costs and is more suitable for promotion.
作者
徐晓华
XU Xiao-hua(Pharmacy Department,Haimen Hospital of Traditional Chinese Medicine,Haimen 226100,China)
出处
《中国实用医药》
2020年第28期164-166,共3页
China Practical Medicine
关键词
氢氯吡格雷
冠心病
成本-效果分析
Clopidogrel tablets
Coronary heart disease
Cost-effectiveness
